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ABSTRACT 
 
The purpose of this review is to investigate the gap in pediatric TB diagnosis and reporting, and 
identify interventions that have been found to be effective in Sub-Saharan Africa. In 2017, one 
million children became infected with TB and 230,000 of these children died. With early 
diagnosis, child mortality resulting from TB infection can be prevented. TB manifests differently 
in children; thus, most conventional diagnostic tools fail. In Sub-Saharan Africa alone, it is 
estimated that 20% of all active TB cases are in children. Since childhood TB is a major public 
health issue, there is a dire need for better diagnostics and reporting systems. Moreover, TB is 
the leading cause of death in HIV positive individuals making it important to discuss HIV status 
and other comorbidities affecting diagnosis and reporting of pediatric TB. BCG vaccination can 
also interfere with TB diagnosis and high BCG vaccination rates make accurate diagnosis 
difficult due to cross reactivity with some diagnostic methods. Many children in high TB 
endemic areas like Sub-Saharan Africa suffer from severe acute malnutrition which complicates 
early diagnosis in children.  For the purpose of this review, HIV positive individuals and 
malnutrition status will be included in the analysis as well as BCG vaccination rates because all 
pose challenges to diagnosing childhood TB in Sub-Saharan Africa. 
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1.0  INTRODUCTION 
1.0 MTB PATHOGENESIS 
Tuberculosis is caused by the bacterium Mycobacterium tuberculosis (Mtb). Mycobacteria are 
slow growing acid-fast bacilli that live inside phagocytes including macrophages and have a high 
concentration of mycolic acids found in the bacterial cell wall (Glickman et al., 2001). This 
characteristic is the basis of some diagnostic tools used to detect presence of the bacterium. In 
addition to the presence of mycolic acids, the cell wall also contains waxy components which 
serve as another virulence factor (Glickman et al., 2001). Mycobacteria have protein secretion 
systems contribute to their virulence. ESX1-ESX5 play integral roles in the secretion of proteins 
that disrupt host immune responses (Glickman et al., 2001). ESX1, encoded by the genomic RD1 
region, secretes the proteins ESAT-6 and CFP-10 that are required for bacterial intracellular 
bacterial survival (Glickman et al., 2001). The secretion of these proteins is the basis for some 
diagnostics that detect the absence or presence of the antigens that these proteins secrete.   
Mtb infection presents differently in children and this poses challenges for diagnostics 
and detection. Granulomas, the lesions associated with TB, are paucibacillary in children, 
meaning there is a small bacterial load making it more difficult for diagnostics to detect disease 
causing positive cases to appear falsely negative (Piccini et al., 2014). Signs and symptoms, to be 
discussed in further detail, often overlap with other diseases experienced in children of high TB 
burden areas making diagnosis more complicated (Orikiriza et al., 2018). 
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1.1 HOST RESPONSE TO MTB 
TB is transmitted via aerosols. Tubercle bacilli can be inhaled by the host through close 
proximity contact with an infected person by activities including talking, coughing, or sneezing 
(Fennelly et al., 2004). Once bacteria enter the host, Mtb are phagocytosed by alveolar 
macrophages (AM) in the alveoli of the lungs (Glickman et al., 2001). Mtb have evolved to 
survive inside of macrophages and will begin to replicate within the AM, eventually spreading to 
other cells nearby (Glickman et al., 2001).With the help of lymphatics, cells can reach parts of 
the body separate from pulmonary tissue and cause extra pulmonary disease (Glickman et al., 
2001).The interaction between the host immune system and the mycobacteria drive formation of 
granulomas. When the host’s adaptive immune response is initiated, granulomas play important 
roles by controlling bacterial growth and restricting it within a confined area, but granulomas 
also provide a site for successful growth of the bacteria (Glickman et al., 2001). 
 The immune response to TB infection in children is different than what is experienced in 
adults. It is estimated that it takes 4-12 weeks from time of infection for a child’s adaptive 
immune response to recognize TB infection (Thomas, 2017). Infants and children have 
downregulated innate cells that ultimately impact the progression to severe active disease 
(Marais et al., 2004). Children are more likely to develop severe forms of disease because the 
innate immune system cannot properly tame infection resulting in lymphatic spread to other parts 
of the body (Marais et al., 2004). The most common types of extrapulmonary disease 
experienced in children are TB lymphoadenitis and TB meningitis (Piccini et al., 2014). TB 
lymphoadenitis is the inflammation of the lymph node and develops around 6 months after 
infection (Piccini et al., 2014). TB meningitis is when infection spreads to the central nervous 
system and is more common in younger children (Piccini et al., 2014). 
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1.1.1 ACTIVE TB INFECTION 
Upon infection with Mtb, it can either result in an active or latent state. Active TB is infectious 
and can be spread to other people through aerosols (Centers for Disease Control and Prevention 
[CDC], 2016). Active TB infection should appear positive on all diagnostic exams (CDC, 2016). 
Clinical manifestations are site specific and correspond to the area of infection (CDC, 2016). 
Pulmonary TB symptoms may include but are not limited to coughing, fever, weight loss, and 
night sweats (Cruz et al., 2007). Extrapulmonary disease may have more serious signs and 
symptoms including adenopathy, tuberculomas, and spondylitis (Cruz et al., 2007). Other 
symptoms exist when infection spreads to other parts of the body. Drug susceptible active TB 
disease could be treated using first line agents Isoniazid, Rifampin, Ethambutol, or Pyrazinamide 
with durations ranging from 6 to 9 months. 
1.1.2 LATENT TB INFECTION  
Latent TB is characterized by the lack of clinical evidence and negative diagnostic results. In 
latent TB, disease cannot be transmitted to other individuals (CDC, 2016). The Tuberculin Skin 
Test (TST) and Interferon Gamma Release Assays (IGRA) can detect latent disease but cannot 
differentiate between the active and latent state (CDC, 2016). If latent disease is detected, proper 
treatment should be started immediately due to the possibility of reactivation to an active state. 
Treatment should be modified to fit the patients’ needs taking into consideration 
immunocompetency and contact with a drug resistant infected individual. Latent TB can be 
treated using Isoniazid, Rifapentin, or Rifampin (CDC, 2016). The lifetime risk of reactivation of 
someone with latent disease is 10% (CDC, 2016). 
4 
1.1.3 HIV INFECTION EXACERBATES TB 
HIV-associated TB is highest in the WHO classified African region (World Health Organization 
[WHO], 2017). Eighty two percent of TB patients also are positive for HIV (WHO, 2017). In 
2017, there were .9 million new cases of TB among HIV-positive individuals with 72% living in 
Africa alone (WHO, 2017). Further, TB is the leading cause of death for HIV-positive people 
(WHO, 2017). In 2016, 40% of HIV deaths were attributable to TB infection (WHO, 2017). HIV 
positive people are 20-30 times more likely to become infected with active TB (WHO, 2017). 
Figure 1 shows the estimated HIV prevalence in new and relapsing TB cases by country in 2016 
(WHO, 2016). 
 
 
 
Figure 1. World map of estimated HIV prevalence in new and recurring TB cases in 2016 
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1.1.4 BCG VACCINE 
The Bacille Calmette-Guerin (BCG) vaccine is made from an attenuated strain of 
Mycobacterium bovis and is the only vaccine available for the prevention of TB (Luca et al., 
2013). BCG vaccination should only be used in people who have not been infected with Mtb and 
are at high risk of exposure to TB (Cernuschi et al., 2018). This vaccine is effective at preventing 
childhood TB but is not as effective for adult prevention (Glickman et al., 2001). It is estimated 
that BCG has a 60-80% vaccine efficacy for children with more severe forms of infection 
including TB meningitis (Roy et al., 2014). It is recommended that a TST be done prior to verify 
the child is not infected with TB (Food and Drug Administration [FDA]).  In endemic countries, 
it is also recommended that an HIV test be done prior to receiving vaccination (WHO, 2018). 
Almost all of Africa, including sub-Saharan Africa, currently has a national BCG vaccination 
policy for all (Mihigo et al., 2017). Figure 3 shows which countries have a national BCG 
vaccination policy (BCG World Atlas, 2017). 
 
1.1.5 MULTI DRUG RESISTANT TB 
Multidrug-resistant TB is defined as a strain of Mtb that is resistant to first line antibiotic 
treatment using Isoniazid and Rifampicin (WHO). Globally, it is estimated that 490,000 people 
developed MDRTB in 2016 (WHO, 2016). Of the estimated incidence of MDRTB cases in 2016, 
only 22% of cases began treatment (WHO, 2016). Extensively drug-resistant TB (XDRTB) is a 
form of MDRTB but has further resistance to second line anti-TB drugs including 
fluoroquinolones and at least one of the following injectable second line drugs Amikacin, 
Capreomycin, Kanamycin, Streptomycin, Ethionamide, Cycloserine, Linezolid, or Clofazimine 
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(WHO). Of the estimated MDRTB cases in 2016, 6.2% were estimated to also be XDRTB 
(WHO, 2016). There is not much data on MDRTB and XDRTB in children because diagnosis is 
difficult leading to underreporting and underdetection. In a mathematical modelling study, it was 
estimated that of the 279,824 child TB cases in the African region, 4,736 of those cases are 
MDRTB (Jenkins et al., 2014). 
1.2 TB DIAGNOSTICS 
1.2.1 TUBERCULIN SKIN TEST/ PURIFIED PROTEIN DERIVATIVE SKIN TEST 
The Mantoux tuberculin skin test (TST) is an intradermal injection of 5 Tuberculin Units of 
purified mycobacterial antigens into the inner surface of the forearm (Huebner et al., 1993). 
Forty-eight to 72 hours after the initial injection, the area of injection needs to be observed by a 
trained health professional and is evaluated using a classification system which measures the 
induration in millimeters (CDC, 2011). If the patient has been exposed to mycobacteria and has 
generated adaptive immunity against mycobacterial antigens, injection will lead to a delayed-
type hypersensitivity response (Huebner et al., 1993). There are different classifications based on 
the background of the patient. The observed millimeter induration decreases as the risk for TB 
infection increases, for example, an HIV positive individual is classified as Mtb positive if the 
purified protein derivative (PPD) injection leads to an induration of 5 or more millimeters while 
for a person with no known risk factors, an induration of 15 or more millimeters is considered 
positive (CDC, 2011). PPD testing is inexpensive, making it an affordable option in low income 
countries. The injection is easy to administer as well as read. Although, it does require more than 
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one visit and lacks specificity in BCG vaccinated individuals which is a problem in countries 
with high BCG vaccination rates. 
1.2.2 INTERFERON GAMMA RELEASE ASSAYS 
Interferon Gamma Release Assays (IGRAs) are blood tests that measure IFN-gamma production 
by antigen-specific T cells in response to ESAT-6 and CFP-10 proteins, two antigens that are not 
present in the BCG vaccine or other mycobacteria (Pai et al., 2008). The measurement of IFN-
gamma can be done by ELISA or ELISpot tests (QuantiFERON-TB Gold In-Tube and T-SPOT 
TB, respectively). IGRAs can detect both latent and active Mtb infection but cannot differentiate 
these states. When using an ELISA-based test, a patient is characterized as positive for Mtb if the 
IFN-gamma concentration is greater than or equal to 0.35 IU/ml (Qiagen Group, 2017). When 
using the ELIspot test, a positive result is reported when the number of IFN-gamma producing 
cells (SFU) is greater than eight in the TB antigen wells (Oxford Immunotec, 2018). IGRA 
testing is more expensive than PPD testing and requires specialized equipment in an appropriate 
laboratory environment. The assay is not as simple to read as PPD testing and requires more 
training of laboratory personnel. 
 
1.2.3 MICROBIOLOGIC DIAGNOSIS 
Acid fast staining can be done on sputum or other specimens from the patient including 
cerebrospinal fluid, blood, pleural effusions, or tissue from a suspected TB case. Ziehl-Neelson 
staining uses multiple reagents including primary stain Carbol Fuchsin, decolorizer acid-alcohol, 
and counterstain methylene blue which will differentiate between non-acid fast bacilli and acid 
fast bacilli (Hussey & Zayaitz, 2018). Acid fast bacilli will retain the primary color red and non-
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acid fast bacilli will wash clear after decolorization and retain the counterstain blue color. The 
presence of acid-fast bacilli are indicative of Mtb infection (Hussey & Zayaitz, 2018). Another 
popular stain to detect Mtb is auramine-rhodamine. Auramine-rhodamine staining uses 
fluorescence microscopy as a readout. This stain uses Auramine Rhodamine solution as the 
primary stain, acid alcohol as the decolorizer and potassium permanganate as the counter stain 
(Hussey & Zayaitz, 2018). Acid fast samples will retain the primary stain and appear red/orange 
against the dark background and non-acid fast samples will not fluoresce against the dark 
background or might appear a very light yellow (Hussey & Zayaitz, 2018). Microbiologic 
diagnosis requires a specialized laboratory environment and properly trained laboratory 
personnel. 
1.2.4 NUCLEIC ACID AMPLIFICATION TEST 
The most common NAAT used is the Xpert MTB/RIF (Cepheid, 2015). Xpert simultaneously 
tests patient samples for TB and Rifampicin resistance. GeneXpert is a qualitative, real time PCR 
diagnostic test that uses probes to identify gene segments specific to Mtb. The primers used 
amplify portions of the rpoB gene and differentiate between mutated and nonmutated sequences. 
Rifampicin resistance is caused by a mutated rpoB gene. Rifampicin targets the products of the 
Mtb rpoB gene and when it is mutated, Rifampicin can no longer bind the RNA polymerase 
making it lose its antimicrobial properties (Telenti et al., 1993). Probe thresholds are set and used 
for MTB/RIF analysis. Mtb is detected if it has a total cycle threshold (CT) value of less than 2 
(Cepheid, 2015). RIF resistance is detected if the CT is greater than 4.0 (Cepheid, 2015). RIF 
resistance is not detected when less than 4.0 (Cepheid, 2015). Mtb is not detected when there is 
none or only one positive probe found (Cepheid, 2015). For easy interpretation, a lab technician 
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does not have to calculate the test results on their own and instead, the instrument will indicate 
whether Mtb and RIF is detected. The turnaround time is less than 2 hours allowing for diagnosis 
and treatment to be done in one initial visit. Xpert only detects resistance to Rifampicin and does 
not perform full drug susceptibility testing. Xpert technology is more expensive and requires a 
specialized laboratory environment in addition to reliable electricity. 
1.3 GLOBAL TB BURDEN 
Mtb ranks number nine for the leading cause of death worldwide. It is the number one cause of 
death by a single infectious agent (WHO, 2017). Although there has been progress made in 
decreasing mortality and incidence rate, it still poses as a serious public health issue. In 2016, 
10.4 million people suffered from TB infection (WHO, 2017). This number is disproportionate 
among different demographics. Ninety percent were adults, 65% were male, 10% were living 
with HIV (with 75% of cases in Africa alone), and 56% of all cases were in five countries: India, 
Indonesia, China, the Philippines and Pakistan (WHO, 2017). Of the cases notified in 2016, 6.9% 
were estimated to be children under age 15 (WHO, 2017).  
1.3.1 SUB-SAHARAN AFRICA  
It is estimated that by 2030, the number of children under 18 in Sub-Saharan Africa will increase 
from 496 million in 2015 to 661 million (United Nations International Children's Emergency 
Fund [UNICEF],2015). Forty five percent of the population in Sub-Saharan Africa is under the 
age of 15 (UNICEF,2015). The increasing number of young people also increases the risk of 
acquiring TB infection. Infectious diseases like TB can partially explain the typical pyramid 
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shape of Sub-Saharan Africa’s population. Figure 2 shows the population pyramid of Sub-
Saharan Africa. The health profile of Sub-Saharan Africa impacts the overall burden of TB 
experienced in children and proves as a serious challenge in diagnosis and reporting. 
 
 
Figure 2. 2017 Population pyramid for Sub-Saharan Africa 
 
 
Sub-Saharan Africa alone, accounts for greater than 70% of the world’s HIV infection 
(Kharsany et al., 2016). Of the 1.5 million AIDS related deaths in 2013, Sub-Saharan Africa 
accounted for 74% of that total (Kharsany et al., 2016). Ninety percent of children in the world 
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suffering from HIV infection also live in Sub-Saharan Africa (WHO, 2015b). Seventy-nine 
percent of HIV/TB coinfections are in Sub-Saharan Africa (Lawn et al., 2009). Since HIV 
weakens the immune system, it increases the risk for active TB infection. Individuals who are 
coinfected with HIV/TB should receive treatment for both pathogens because each disease 
exacerbates one another (Lawn et al., 2009). Further, treating HIV reduces the risk for the 
development of active TB infection by restoring the host immune system (Lawn et al., 2009).  
Globally, one third of children that suffer from malnutrition live in Sub-Saharan Africa 
(Adler et al., 2017). Ten percent of children under 5 years old die from severe acute malnutrition 
(SAM) (Adler et al., 2017). Malnutrition is a significant risk factor for development of childhood 
TB, especially in countries with high rates of TB (Adler et al., 2017). Malnutrition is also 
associated with fatal outcomes in Mtb-infected children because nutrition plays an integral role 
in the development of immune responses specific to Mtb (Adler et al., 2017). It is important to 
take into consideration the implications of malnutrition and the relationship it has on childhood 
TB and diagnosis. 
The BCG world atlas is a database of global BCG vaccination practices which is current 
as of 2017. All Sub-Saharan African countries currently have national BCG vaccination 
programs where the first BCG vaccination occurs at birth, with some countries recommending a 
booster later in life (Zwerling et al., 2011). Figure 3 shows BCG vaccine policies by country 
(BCG World Atlas, 2017). Protein used in the BCG vaccine cross-reacts with PPD used in the 
TST diagnostic tool. High BCG vaccination in Sub-Saharan Africa needs to be taken into 
consideration when interpreting diagnostic results.  
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Figure 3. World map of current and past BCG vaccination policies by country 
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2.0  METHODS 
A literature search of the different Mtb diagnostic methods used for children in Sub-Saharan 
African countries was conducted using the PubMed online scientific database. Different search 
queries were used including MeSH terms relevant to this topic. MeSH terms included but were 
not limited to Sub-Saharan Africa OR all countries included in Sub-Saharan Africa, AND 
Tuberculosis, diagnosis, AND pediatric OR children. Figure 4 is a screenshot of the history of 
the query builder in PubMed with every MeSH term included in the search. All searches were 
filtered by age (birth-18 years) and language (English). 
Titles and abstracts were screened first to discard any studies not relevant to the topic of 
this review. The study had to include children <18 years of age, one of the diagnostic methods 
discussed in the introduction used to detect TB, and had to be done in a Sub-Saharan African 
country as defined by the United Nations Development Program (United Nations Development 
Programme [UNDP], 2018). Studies including adult and child age groups were considered if 
results/discussions discussed the efficacy of diagnostic tools specifically in the child age groups. 
A list of all African countries in the Sub-Saharan region are in Table 1. 
 
 
Figure 4. Screenshot of PubMed advanced search builder used to find relevant studies 
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Table 1. Countries in Sub-Saharan African region as classified by the United Nations 
 
 
Countries	in	
Sub-Saharan	
Africa		
	  
Angola	 Eritrea	 Mauritius	 Tanzania	
Benin	 Ethiopia	 Mozambique	 	Togo	
Botswana	 Gabon	 Namibia	 Uganda	
Burkina	Faso	 Gambia	 Niger	 Zambia	
Burundi	 Ghana	 Nigeria	 Zimbabwe	
Cameroon	 Guinea-Bissau	 Rwanda	 	
Cape	Verde	 Kenya	
Sao	Tome	and	
Principe	 	
Central	African	Republic	 Lesotho	 Senegal	 	
Chad	 Liberia	 Seychelles	 	
Comoros	 Madagascar	 Sierra	Leone	 	
DRC	 Malawi	 South	Africa	 	
Cote	d'Ivoire	 Mali	 South	Sudan	 	
Equatorial	Guinea	 Mauritania	 Swaziland	 	
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3.0  RESULTS  
3.1 DIAGNOSIS OF ACTIVE TB INFECTION 
3.1.1 PULMONARY TUBERCULOSIS DISEASE 
Bacha et al. (Bacha et al., 2017), did a retrospective descriptive study on children less than 15 
years of age in Tanzania who were suspected of active TB infection. Sputum samples were 
collected and sputum induction was performed on children who were unable to expectorate. 
Smear microscopy and Xpert were performed on the first sputum sample and culture was 
performed on a second sample when available. They used clinical diagnosis as a reference 
standard for Xpert. Sensitivity of Xpert and smear microscopy were 8% and 6% respectively 
with Xpert only being half as sensitive as culture. This study emphasized the importance of using 
clinical standards to diagnose TB and that Xpert should not replace culture but instead be used in 
addition to these other diagnostic algorithms. 
Walters et al. (Walters, Demers, et al., 2017) addressed the difficulty of obtaining sputum 
samples from children suspected of having TB infection and the difficulty in performing sputum 
induction in resource limited settings. The aim of this study was to see if stool can be used for 
the rapid identification of TB in children. Children less than the age of 13 years showing signs of 
TB gave one sputum sample and one stool sample. Smear microscopy, culture, and Xpert were 
all performed on sputum cultures and Xpert was performed on stool samples. Walters et al. 
wanted to evaluate the sensitivity and specificity of using a stool sample compared to sputum 
sample in common diagnostic methods. Using bacteriologic confirmation, stool Xpert had a 
31.9% sensitivity and a 99.7% specificity. Stool Xpert only detected Rifampicin resistance in 
25% of microbiologically confirmed resistant cases. Stool Xpert was only truly positive in 
16 
children with severe clinical disease suffering from comorbidities such as HIV/AIDS and severe 
acute malnutrition. 
In another study, Walters et al (Walters, van der Zalm, et al., 2017) evaluated stool 
cultures as a replacement to sputum in the detection of TB infection in children. The sensitivity 
of stool culture in reference to sputum culture yielded a sensitivity of 24%. Testing the same 
stool sample using Xpert increased sensitivity to 33.3%. As described in (Walters, Demers, et al., 
2017), stool Xpert had a higher sensitivity than stool culture (31.9% and 24% respectively). 
Testing stool by culture enables full drug sensitivity testing whereas Xpert only detects 
Rifampicin resistance. Walters recommended the usefulness of combining the two testing tools 
together improving the sensitivity and allowing full drug sensitivity testing. The sensitivity of 
stool Xpert was found to be higher in this study when compared to other studies that found 
sensitivities between 15-20%. The difference in stool sample preparation and processing used in 
previous studies can contribute to the differences in results. Walters concluded that stool culture 
cannot substitute sputum culture and Xpert for diagnosing childhood TB but can be a useful 
addition to diagnostic algorithms where sputum cannot be obtained. 
Chipindero et al. (Chipinduro et al., 2017) found similar results as Walters et al.  
(Walters, van der Zalm, et al., 2017). Chipindero et al. used a cross-sectional approach to study 
5-16 year olds in Zimbabwe. They tested one sputum sample and one stool sample using Xpert. 
They used microbiologically-confirmed TB by smear microscopy, culture, and Xpert using 
sputum as a reference standard. Stool Xpert yielded a sensitivity of 68% and a specificity of 
98%. Sensitivity was highest in HIV positive children compared to children not infected with 
HIV which was found in other studies. The conclusions previously made in stool Xpert studies 
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were made here. It should be used as an alternative when sputum is unavailable and if possible a 
second stool sample can significantly increase the sensitivity of the test.  
Orikiriza et al. (Orikiriza et al., 2018) did a prospective cohort study on children from one 
month to fourteen years of age suspected of TB infection at a referral hospital in Uganda. They 
wanted to compare using sputum and stool specimens with Xpert. Two sputum samples were 
taken from children in addition to a stool sample. All samples were tested using Xpert, culture, 
and smear microscopy (except stool samples). Thirty one percent of children participants were 
also HIV infected. Four percent of children were also microbiologically confirmed to have TB. 
Sputum Xpert compared to culture had a sensitivity of 90.9% and a specificity of 99.1%. Stool 
Xpert compared to stool culture had a 55.6% sensitivity and 98.2% specificity. They also 
assessed patient characteristics associated with positive results. Culture detection yield was more 
than two times higher in children older than 10 years old and children that provided at least one 
sputum sample between the ages of 5 and 10 had the highest collection yield. Less than age 5 
was associate with the lowest detection yield. This was expected due to the low bacterial load 
experienced in younger children in addition to the poor quality of samples collected. The results 
of this study show sputum sample is still better than stool for both Xpert and culture. 
Bates et al. (Bates et al., 2013) evaluated the ability of using gastric lavage aspirates in 
children suspected of having TB as a method for sample using Xpert. Children fifteen years of 
age or younger in Zambia provided sputum samples by gastric lavage aspiration and sputum 
induction. Common comorbidities in this sample were malnutrition (22.6%), GI illness (17.9%), 
and respiratory disorders (34.6%). This study found no significant difference in the sensitivity 
between sputum and GLA samples using Xpert. Xpert was found to be more sensitive in both 
sputum and GLA compared to culture. HIV positive children were found to have significantly 
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lower bacterial loads compared to HIV negative children. Samples from older children yielded 
higher bacterial loads compared to younger children when looking at TTP in MGIT culture. 
Researchers concluded that GLA is more valuable than sputum induction because it does not 
require a professional, proper equipment, or additional staffing and can be readily applied in 
resource limited settings.  
Pohl et al. (Pohl et al., 2016) aimed to evaluate the possibility of using whole blood with 
Xpert as a sample to detect TB in children. In young children, there is a high prevalence of occult 
hematogenous spread and disseminated disease and this makes sampling blood a potential 
approach to detect Mtb in children. Children between 2 months of age and 16 years of age 
provided a blood AND sputum sample. Less than 50% of children with culture confirmed TB 
were also HIV infected and 95% of children were BCG vaccinated. Whole blood Xpert had a 
sensitivity of 7.1% compared to culture confirmed disease. A similar study found similar results 
that Mtb was rarely found in whole blood of children regardless of HIV status. Small blood 
volumes (1 mL) were used in this study compared to adult studies which collect 2-20 mLs of 
blood.  
Rose et al. (Rose et al., 2012) evaluated the Quantiferon Gold TB In Tube performance 
for diagnosing TB in children less than 15 years of age in Tanzania. Children provided blood for 
IGRA and HIV testing, and sputum for smear microscopy and culture. TST procedure was done 
on children as well as a chest x-ray. QFT and TST had sensitivities of 19% and 6% respectively 
with specificities 90% and 98% respectively. They compared sensitivities of QFT and TST in 
adults for diagnosing already confirmed TB disease. QFT and TST had significantly higher 
sensitivities in adults (86% and 89% respectively). Indeterminate diagnostic results were 
correlated with young age, HIV positivity, and malnutrition status. The study concluded that T-
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cell based assays like QFT and TST perform poorly in children with immature or compromised 
immunity and indeterminate results were a predictor of fatal outcomes in children.  
Sekadde et al. (Sekadde et al., 2013) in a cross-sectional study design focused on 
hospitalized children aged 2 months to 12 years suspected of TB infection. They evaluated Xpert 
against smear microscopy and culture. Sensitivity of Xpert using culture as a reference was 
79.4%. Using clinical diagnosis as a reference, Xpert yielded a 96.5% sensitivity. They also 
looked at clinical characteristics that were associated with a positive Xpert result. Children older 
than 5 years of age, having a positive TST result, and a positive TB contact history were all 
significantly associated with a positive Xpert result. DST was not performed so the sensitivity of 
Xpert detecting Rifampicin resistance was not calculated. There were significantly higher 
contaminated culture results when compared to indeterminate results given by Xpert. Sekadde 
emphasized the importance of clinically evaluating children with negative culture results given 
the low sensitivity of culture in children and the high probability of TB infection. 
A similar study done by Togun et al. (Togun et al., 2015), evaluated Xpert in children 
less than 15 years of age in an outpatient setting in Gambia. One induced sputum sample was 
taken from child contacts of TB positive adults and was testing using smear microscopy, culture, 
and Xpert. Smear and Xpert had sensitivities of 28.6% and 42.9%. There was a 19.4% increase 
in case detection using Xpert compared to smear microscopy. Using Xpert and culture combined 
yielded a sensitivity of 32.3% but with no significant difference combining all three methods. 
With all TB diagnosis and treatment used as a reference, given the low sensitivity culture yields 
on children, gave an increase of 9.7% to 22.6% compared to culture, smear, and Xpert tests 
alone.  
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Lacourse et al. (LaCourse et al., 2014) hypothesized that severely malnourished 
hospitalized children would have a high prevalence of TB detected by Xpert compared to 
microscopy and culture methods. Using a prospective observational study design, one induced 
sputum sample was taken from all children suspected of TB between the ages of 6 months and 
60 months of age. Ninety eight percent of child patients were able to provide 2 sputum samples. 
HIV prevalence in the sample was 18% and 98.3% were BCG vaccinated. Xpert provided 100% 
sensitivity and 99.6% specificity when compared to culture. Smear only yielded a sensitivity of 
50% and specificity of 100% compared to culture. There was a significant higher mortality rate 
among HIV infected children compared to HIV uninfected children. They emphasize that using 
confirmed and probable TB cases most likely is more representative of the burden experienced in 
this group and recommend clinical diagnosis of TB with a low treatment threshold in children 
living with malnutrition, TB, and HIV.  
Zar et al. (Zar et al., 2012) examined the possibility of using nasopharyngeal aspirates 
(NPA) as a specimen type to diagnose TB in children. They compared NPA and IS samples with 
smear, culture, and Xpert. In a previous study done by Zar and colleagues, they found that 
running 2 Xpert tests detected 76% of microbiologically confirmed TB using induced sputum 
samples. The goal of this study was to compare the diagnostic accuracy of using multiple NPA 
samples and IS samples with smear, culture, and Xpert. Twenty one percent of children less than 
fifteen years of age included in this study were HIV infected. Smear was 34.5% sensitive 
compared to culture and Xpert was 80.5% sensitive compared to culture. Xpert detected 100% of 
all cases detected by smear. Using culture from either NPA or IS, two Xpert tests on NPA 
yielded 65.1% and 71.4% with IS. Using both samples, the sensitivity of Xpert increased to 81%. 
Second samples obtained on a different day were more valuable than samples obtained the same 
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day hours apart. Because of the low sensitivity of culture, 76% of children were treated for TB 
based on clinical diagnosis. Zar et al. concluded that Xpert testing on 2 NPA samples should be 
recommended when IS cannot be performed and culture is not an option. 
In a prospective cohort study, Rachow et al. (Rachow et al., 2012) compared smear 
microscopy, culture, and Xpert. The goal was to explore the performance of Xpert and to look at 
the impact on time between diagnosis and treatment in children 6 weeks to 14 years of age in a 
referral hospital. All children were assessed clinically by TST, blood collection, x-rays. Each 
provided up to 3 sputum samples with IS performed when needed. More than 50% of children 
enrolled were HIV infected. The study showed that providing second and third samples increased 
sensitivity by 20% and 13% respectively. Xpert results were not influenced by HIV status. Xpert 
detected 3 times more culture confirmed cases than smear microscopy. Compared to culture, 
Xpert had a sensitivity of 66.6%. Xpert detected an additional 16% of TB infected children that 
were not confirmed by culture but were clinically indicative of TB infection. This study 
demonstrated the importance of collecting multiple samples when possible and that Xpert could 
increase TB case identification and decrease time between diagnosis and treatment. 
 
3.1.2 EXTRAPULMONARY DISEASE 
Blok et al. (Blok et al., 2014) evaluated the usage of Lipoarabinomannan ELISA for early 
detection of pediatric TB meningitis. Lipoarabinomannan is an Mtb-specific lipopolysaccharide 
found in the bacterial cell wall. LAM is released when mycobacteria disintegrate into the 
bloodstream where it is eventually excreted in the urine. Children from 3 months of age to 13 
years of age suspected of TB meningitis were evaluated. Urine was compared to cerebrospinal 
fluid smear positive and culture positive samples. It was found to have a sensitivity of 4.8% and 
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a specificity of 93.1%. A higher sensitivity was found in HIV positive children because they tend 
to have more severe disease with higher bacterial loads and a decreased capacity to contain 
infection causing the increase excretion of LAM in the urine. They concluded that urinary LAM 
was of little value for the diagnosis of TB meningitis in children. 
Bholla et al. (Bholla et al., 2016) studied children from 8 years of age to 16 years of age 
in Tanzania to evaluate the use of fine needle aspirates (FNA) and Xpert to diagnose TB 
lymphoadenitis. In two-thirds of cases, children with extrapulmonary TB present with TB 
lymphoadenitis. FNA of lymph nodes were taken from children suspected of TB and analyzed 
using smear microscopy, liquid culture, cytology, Xpert, and easyNAT. Xpert had a sensitivity 
and specificity of 56% and 96% compared to standard culture method. This study found a high 
proportion of invalid results in addition to 48% of the cultures being contaminated. Bholla et al. 
concluded that Xpert was not an appropriate stand-alone method to diagnose extra pulmonary 
TB in children and that diagnosis should be done using clinical assessment, culture, and Xpert. 
Held et al. (Held et al., 2016) used a prospective study approach to compare Xpert with 
culture and histology to diagnose pediatric musculoskeletal TB. Children under the age of 13 
presenting to a hospital with suspected musculoskeletal TB provided two specimens. One 
specimen was processed and used for Xpert and the other was used for culture and histology. 
HIV status was only provided for 29.4% of the children with 10% being HIV infected. Using 
culture and histology as a reference, Xpert yielded a sensitivity of 73.9% with a specificity of 
100%. The sensitivity and specificity of culture against histology was 60.9% and 100% 
respectively. Smear microscopy had a sensitivity of 60.9% and specificity of 98.8% against 
culture and histology. Xpert had a significantly shorter turnaround around time compared to 
culture (0.8 days and 21 days respectively). Xpert detected more cases compared to culture. 
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Culture detected two cases of multi-drug resistant TB that was not detected by Xpert. The 
pediatric TB diagnostic algorithm at this hospital in Cape Town, South Africa is to use Xpert and 
histology together.  
Solomans et al. (Solomons et al., 2015) wanted to evaluate using more than one NAAT to 
diagnose TB meningitis in children ranging from 3 months of age to 13 years in South Africa. 
They compared Xpert and Genotype assays using CSF of children suspected of TB meningitis. 
They obtained CSF by using lumbar puncture. When they combined any positive NAAT result it 
provided a sensitivity of 49%. Smear microscopy and culture using CSF had a sensitivity of 4% 
and 26% respectively. The two NAATs in addition to the culture had the highest sensitivity of 
56% and a specificity of 98% compared to culture alone which was 22% and 100% respectively. 
They concluded that using NAATs can increase accuracy of diagnosis when performed on CSF 
in addition to culture. 
3.2 DIAGNOSIS OF LATENT TB INFECTION (LTBI) 
Adetifa et al. (Adetifa et al., 2010) compared the ability of IGRA and TST to detect latent TB in 
children. The risk of progression from latent TB to active TB is highest in children and HIV 
infected children. Adetifa et al. followed 6 month olds to 14 year old children in Gambia that 
were in contact with TB infected adults. TST was the most responsive to TB exposure compared 
to the IGRA. Low HIV incidence in Gambia and this sample specifically having low BCG 
vaccination rates (59.1%) might not be realistic in other Sub-Saharan African countries. 
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4.0  DISCUSSION 
4.1 ACTIVE DISEASE 
 
4.1.1 CULTURE, THE GOLD STANDARD 
Culture is still considered the gold standard for detection of TB infection in children. Culture has 
a low sensitivity of 60% and fails to detect 40% of all infected children (Schumacher et al., 
2016).  Culture has a long turnaround time of up to 42 days. This increases the time between 
detection and initiation of treatment. Decision to treat should not only be influenced by a positive 
culture result. Clinical diagnosis needs to be taken into consideration due to the low sensitivity of 
culture. The series of studies above compared different diagnostic methods to culture as a gold 
standard to diagnose pediatric Mtb infection. The studies determining the sensitivity and 
specificity of culture used clinical diagnosis as a reference. 
 
4.1.2 SMEAR MICROSCOPY 
Smear microscopy relies on the presence of acid fast bacilli. Mtb in children is paucibacillary 
making it more difficult to detect by smear microscopy. As discussed above, smear microscopy 
is less sensitive in HIV positive and severely ill children (Mosissa et al., 2016). Smear 
microscopy also does not detect MDRTB delaying treatment until results from DST are 
available. Every study in this review had low smear microscopy sensitivities compared with 
other diagnostics. Sensitivity of smear microscopy is lower in younger children compared to 
older children who present with higher bacterial load. 
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4.1.3 XPERT MTB/RIF 
Ever since the WHO endorsed Xpert MTB/RIF assay in 2011, there have been many studies 
evaluating its effectiveness against other methods of detection. Xpert has a short turnaround time 
of 2 hours decreasing the time between diagnosis and treatment. Treatment can be initiated the 
same day as diagnosis. Xpert was sensitive in HIV infected and malnourished children, which 
are common comorbidities in high TB burden areas. Xpert simultaneously detects Rifampicin 
resistance. Xpert is hands-free, thus limiting exposure risks to technologists, is simple to run and 
interpret results. All studies above evaluating Xpert make the recommendation of using culture, 
clinical assessment, and Xpert as a diagnostic algorithm to detect childhood TB and that Xpert 
cannot be used on its own. Studies showed increased sensitivity of Xpert in older children who 
present with adult-type infection. Similarly, collecting more than one sample for any specimen 
type also increased sensitivity. 
 
4.1.4 CLINICAL ASSESSMENT 
Clinical assessment was found to be important when diagnosing and treating children with TB. 
Given that culture, the gold standard, still misses a lot of cases, many children are diagnosed 
clinically without microbiological confirmation.  
 
 
4.2 LATENT DISEASE 
 
TST and IGRA are the only diagnostics available that detect both active and latent TB infection. 
Although they detect both, they cannot differentiate between the two forms. There are high BCG 
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vaccination rates in Sub-Saharan Africa. BCG vaccination cross reacts with the TST diagnostic. 
IGRAs are more sensitive than TST in children. The study done by Rose et al. showed that the 
performance of these two tests were affected by the immaturity of the immune system in young 
children and the impaired immune system experienced in severely ill children (Rose et al., 2012). 
There are few studies in Sub-Saharan Africa focusing on the diagnosis of latent TB in the 
pediatric population. Contact tracing studies are costly and require a lot of time to complete. 
Since the activation of latent TB disease to active TB disease is most common in young and 
immunocompromised children, latent TB diagnosis and treatment is very important.  
The progression of latent TB infection to active TB infection in children can be prevented 
by contact tracing adults who are Mtb positive. When a child is exposed to Mtb, the five-year 
risk for developing active TB in children under five years and 5-14 year olds is 33% and 20% 
respectively (Mandalakas et al., 2015). Further, risk is highest in the first year after exposure and 
in children who are immunocompromised. Children exposed to TB before age 1 have a 50% 
chance of developing disease if treatment is not initiated (Mandalakas et al., 2015). If latent 
disease is detected, there are treatment options to prevent activation into clinical disease. It is 
difficult to detect latent disease in children in endemic TB areas due to a myriad of reasons. First, 
children in high endemic areas are BCG vaccinated which causes cross-reactivity with the TST 
(one of the latent TB diagnostics). In Sub-Saharan Africa, there is a BCG vaccination policy and 
the majority of children are vaccinated at birth. There is no gold standard for latent TB detection. 
Most studies use recent contact as a reference standard which can cause either false positive or 
false negative results. Also, children who are severely ill can have indeterminate diagnostic 
results and fatal outcomes.  
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Children in Sub-Saharan Africa suffer from serious comorbidities which can impact 
interpretation of results. 
 
4.3  USING SAMPLES OTHER THAN SPUTUM 
 
Using samples other than sputum for the diagnosis of pediatric TB is attractive due to the 
difficulty of obtaining sputum samples from children. Also, disease is paucibacillary and less 
cavitary in children making detection using sputum a challenge. In this review, sputum 
(expectorated and induced), NPA, GLA, FNA, whole blood, and urine were all reviewed as 
possible specimens with culture and Xpert. For extrapulmonary TB, it is more useful to diagnose 
using specimens specific to the area of infection. A study using CSF as a specimen to diagnose 
TB meningitis found a sensitivity of 22% for Xpert compared to 24% using culture(Solomons et 
al., 2015). The low CSF volumes in children made it difficult to obtain enough with culture 
having a higher sensitivity than Xpert (Solomons et al., 2015). Stool is easy to obtain from 
children given that that swallowed sputum remains in the stool (Walters, Demers, et al., 2017). 
The four studies in the review that used stool samples had the limitation of all using different 
stool processing protocols (Chipinduro et al., 2017; Orikiriza et al., 2018; Walters, Demers, et 
al., 2017; Walters, van der Zalm, et al., 2017). Stool had a higher yield when used on severely ill 
children (Chipinduro et al., 2017; Walters, Demers, et al., 2017; Walters, van der Zalm, et al., 
2017). It was also found to have an increased sensitivity in children older than 10 years 
(Orikiriza et al., 2018). It is still not recommended that stool should replace sputum given 
sputum sensitivity was higher over stool sensitivity using both Xpert and culture. Studies using 
GLA reported that there needs to be a minimum of 2 samples for it to be effective (Bates et al., 
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2013). To diagnose TB lymphadenitis, FNA samples were used. Two thirds of EPTB patients 
present with lymphoadenitis making FNA samples useful (Bholla et al., 2016). Xpert using FNA 
had a 56% sensitivity compared to culture (Bholla et al., 2016).  One study used whole blood as 
a sample. Whole blood is easy to draw and blood infection is common in disseminated TB 
infection (Pohl et al., 2016). They found a lower sensitivity when using Xpert compared to 
culture (7.1%) (Pohl et al., 2016). A limitation was using small blood volumes compared to what 
is typically used in adults (2-20mLs) (Pohl et al., 2016). Zar et al. compared the sensitivity of 
NPA and IS specimens and found that two Xpert tests on NPA yielded a sensitivity of 65.1% 
compared to 71.4% with IS (Zar et al., 2012). They found the incremental value of collecting 
more than one samples and running multiple tests (Zar et al., 2012). Blok et al. used urine as a 
specimen compared to CSF for diagnosing TB meningitis and found a low sensitivity of 4.8% 
using CSF and culture as a reference (Blok et al., 2014). 
 
4.4  LABORATORY AND PERSONNEL CAPACITY 
 
A quality assurance study was done in Ethiopia assessing AFB smear microscopy performances 
in health facilities using the Ethiopian National Reference Laboratory Guidelines. Forty one 
percent of laboratories reported back ‘unsatisfactory’ in regards to reading AFB slides correctly 
(Mosissa et al., 2016). The minimum number of acid fast bacilli needed to produce a positive 
slide has been estimated to be in between 5,000 and 10,000 bacilli/mL of sputum and if it is 
below 1,000 the chance of observing it on the slide is less than 10% (Moro et al., 2010). 
Unreliable lab results can misdiagnose patients with active TB infection delaying treatment and 
allowing the possibility of transmission to other susceptible individuals. Most countries in Sub-
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Saharan Africa rely on sputum microscopy to diagnose TB. In addition to the poor quality of 
microscopy procedure in low resource settings, children have low bacterial loads making it even 
more difficult to detect. This is even more so a problem in HIV infected and severely ill children 
which is endemic in Sub-Saharan African countries.  
There is also a lack of prime culture facilities in low resource settings like Sub-Saharan 
Africa. Culture is still the gold standard to diagnose TB in children and adults. Culture has a long 
turnaround time of up to 42 days making the time between diagnosis and treatment delayed. A 
survey done by Saito et al. was administered to 663 health care services in 9 Sub-Saharan 
African countries to determine the proportion of facilities equipped with proper TB diagnostic 
tools(Saito et al., 2012). Mtb culture was only available at 53% of health care facilities only 
reaching 77% of patients (Saito et al., 2012). The survey also found that primary health care 
services had the lowest access to diagnostics compared to secondary and tertiary services (Saito 
et al., 2012). Diagnosis and treatment is typically based off of clinical assessment. 
A cross-sectional study done in Nigeria examined the gaps in knowledge and training that 
clinicians experience in management of TB. Ninety four percent of clinicians reported that 
diagnosis of childhood TB is a problem in Nigeria (Chukwu et al., 2016). Sixty four percent 
reported having ‘good’ knowledge of TB in children (Chukwu et al., 2016). Out of the clinicians 
who participated, 13.2% were pediatricians and of those 20.8% were considered specialized in 
pediatric care (Chukwu et al., 2016). Only half could correctly identify symptoms experienced in 
TB infected children (Chukwu et al., 2016). Ninety five percent of clinicians agreed that 
additional training on the use of the TB screening score chart could significantly improve 
pediatric TB diagnosis (Chukwu et al., 2016). Respondents also reported that childhood TB 
could be controlled if TB in adults could be improved (Chukwu et al., 2016).  
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4.5  COMORBIDITIES 
 
Tuberculosis, HIV, and malnutrition are individually associated with high disease burdens in 
Sub-Saharan Africa. Co-infection exacerbates severe illness experienced in children (Adler et al., 
2017). Malnutrition is associated with fatal outcomes in pediatric TB and HIV infected children 
(Adler et al., 2017). Ten percent of mortality in children under age five is attributed to severe 
acute malnutrition (Adler et al., 2017). Further, a study found that 10% of HIV positive children 
on antiretroviral therapy also had severe acute malnutrition (Adler et al., 2017). HIV and 
malnutrition in children in Sub-Saharan Africa make diagnosing TB even more difficult. The 
wide spectrum of disease experienced in TB infected children commonly overlap with the signs 
and symptoms of these other comorbidities (Orikiriza et al., 2018). HIV status was not known in 
some of the children within these studies. Some parents refused HIV testing for their child and 
other studies used self-reported measures to identify HIV status. HIV prevalence is also diverse 
throughout Sub-Saharan Africa with some rates being substantially lower in some countries 
compared to others. Future diagnostic tools need to take into consideration that TB presentation 
in children suffering from malnutrition and HIV presents differently than in children without 
these common comorbidities. These comorbidities are common in TB endemic countries. 
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5.0  CONCLUSION 
The first pillar in the WHO End TB Strategy focuses on early detection, treatment, and 
prevention for all TB patients (WHO, 2015a). Their aim is to make sure that all patients have 
equal, unhindered access to affordable care but to also engage in their care. The most important 
key component of this pillar is early diagnosis of TB including universal drug-susceptibility 
testing and systematic screening of contact and high-risk groups (WHO, 2015a). In order to 
diagnose pediatric TB at the earliest stage possible, there needs to be an increase in the use of 
diagnostic tools that are highly sensitive and specific for TB which are both currently not 
available due to lack of access and development. Rapid diagnostic tests are not as sensitive in 
children as they are in adults. New diagnostic tools need to be developed that are sensitive 
enough to detect pediatric TB disease and take the common comorbidities experienced in high 
TB burden areas into consideration. Diagnostic tests need to be affordable and practical to those 
in developing countries like Sub-Saharan Africa. There needs to be a fast turnaround time to 
decrease the time between diagnosis and treatment. Pediatric TB under detection is a significant 
public health issue and without sensitive diagnostic tools TB disease will remain endemic. This 
review of the literature should be interpreted as a guide to increase the efficacy of early 
diagnostic tools used in the detection of pediatric TB in Sub-Saharan African countries. 
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APPENDIX: TABLE ON STUDY AND PARTICIPANT CHARACTERISTICS 
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Table 2. Study and participant characteristics 
 
Author,	year	 Country	 Study	Design	 Sample	Population	 Sample(s)	Type	 %	HIV	(+)	 %	BCG	Vaccinated	
Severe	
Malnutrition	
Bacha	et	al.,	2017	 Tanzania	 Retrospective	Descriptive	 <15	years	 Sputum	 53.50%	 	 30.90%	
Walters,	Demers,	et	al.,	
2017	 South	Africa	
Prospective	
Cohort	 <13	years	
Sputum,	GA,	NPA,	
stool	 13.70%	 95%	 N/A	
Walters,	van	der	Zalm,	et	
al.,	2017	 South	Africa	
Prospective	
Cohort	 <13	years	
Sputum,	GA,	NPA,	
stool	 15.4%%	 97%	 N/A	
Chipinduro,	Mateveke,	
Makamure,	Ferrand,	&	
Gomo,	2017	
Zimbabwe	 Cross-sectional	 5-16	years	 Sputum,	stool	 51%	 N/A	
Z-score:	-1.09	(-
1.99-00.46)*	
Orikiriza	et	al.,	2018	 Uganda	 Prospective	Cohort	 1	month-14	years	 	    
Bates	et	al.,	2013	 Zambia	 Prospective	Descriptive	 <15	years	 Sputum,	GLA	 30.50%	 N/A	 N/A	
Pohl	et	al.,	2016	 Tanzania,	Uganda	
Prospective	
Cohort	 2	months-	16	years	
Whole	blood,	
Sputum,	GLA,	FNA	 36%	 95%	 19%	
Rose	et	al.,	2012	 Tanzania	 Prospective	Cohort	 <15	years	 Sputum,	GLA	 37%	 93%	 N/A	
Sekadde	et	al.,	2013	 Uganda	 Cross-sectional	 2	months-12	years	 Sputum	 41.6%	 67.60%	 27.20%	
Togun	et	al.,	2015	 Gambia	 Prospective	Cohort	 <15	years	 Sputum	 0%	 72%	 29%	
LaCourse	et	al.,	2014	 Malawi	 Prospective	Cohort	 6-60	months	 Sputum	 17.6%	 98.3%	 100%	
Zar	et	al.,	2012	 South	Africa	 Prospective	Cohort	 <15	years	 Sputum,	NPA	 21.9%	 N/A	 15.60%	
Rachow	et	al.,	2012	 Tanzania	 Prospective	Cohort	 6	weeks-14	years	 Sputum	 51.2%	 N/A	
Z-score:	-1.8	(-
2.9—0.3)*	
Blok	et	al.,	2014	 South	Africa	 Cross-sectional	 3	months-13	years	 CSF,	urine	 12.1%	 85.7%	 N/A	
Bholla	et	al.,	2016	 Tanzania	 Prospective	Descriptive	 8-16	years	 FNA,	sputum	 20%	 N/A	 N/A	
Held	et	al.,	2016	 South	Africa	 Prospective	Cohort	 <13	years	 Biopsy	 10%
•	 N/A	 N/A	
Solomons	et	al.,	2015	 South	Africa	 Prospective	Cohort	 3	months-13	years	 Sputum,	GLA,	CSF	 15%	 N/A	 N/A	
Adetifa	et	al.,	2010	 Gambia	 Retrospective	Descriptive	 6	months-14	years	 Blood	 1.10%	 59.10%	 N/A	
 
 
 
•=29.4%	of	sample	known	HIV	status	
*=Weight	for	age	Z-score,	classified	by	WHO	
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